Latest News

June 22, 2022
June 22, 2022
Categories

FDA approves dabrafenib plus trametinib for BRAF V600E-mutated tumors based on data from NCI-MATCH

Do you like it?
Read more
June 20, 2022
June 20, 2022
Categories

TMIST breast cancer trial looks to recruit underserved communities

Do you like it?
Read more
June 8, 2022
June 8, 2022
Categories

Dr. Abhishek Tripathi discusses the 8-year survival outcomes from the CHAARTED trial for patients with advanced prostate cancer

Do you like it?
Read more
June 7, 2022
June 7, 2022
Categories

Pancreatic neuroendocrine tumors: Capecitabine plus temozolomide gives longer PFS than temozolomide alone

Do you like it?
Read more
June 7, 2022
June 7, 2022
Categories

E2108 evidence informs a discussion on systemic therapy vs surgery for de novo stage IV breast cancer

Do you like it?
Read more
Load more

Tweets

ECOG-ACRIN Cancer Research Group Follow

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

eaonc
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
24 Jun

#Clinicaltrial EAA171/OPTIMUM’s objective is to determine if the addition of ixazomib to lenalidomide improves overall survival for those with previously diagnosed #multiplemyeloma. Learn more here: https://bit.ly/eaa171optimum #mmsm cc: @myelomaMD @mtmdphd @VincentRK

Reply on Twitter 1540364856188076032 Retweet on Twitter 1540364856188076032 2 Like on Twitter 1540364856188076032 1 Twitter 1540364856188076032
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
24 Jun

You may be eligible to participate in a #rectalcancer study (MSI-H or dMMR) that could discover if treatment w/ #immunotherapy + radiation prior to surgery is better than the usual approach of radiation, surgery, and chemotherapy. More: https://bit.ly/ea2201trial #colorectalcancer

Reply on Twitter 1540334680788111360 Retweet on Twitter 1540334680788111360 Like on Twitter 1540334680788111360 1 Twitter 1540334680788111360
Retweet on Twitter ECOG-ACRIN Cancer Research Group Retweeted
umgccc UMGCCC @umgccc ·
23 Jun

@RaneeMehra, director of head & neck medical oncology, discusses research to de-escalate adjuvant chemoradiation for HPV+ oropharyngeal cancer patients treated with transoral surgery as a way to reduce debilitating side effects. @eaonc sponsored the study. https://bit.ly/3HOUGtV

Reply on Twitter 1540067602986201088 Retweet on Twitter 1540067602986201088 1 Like on Twitter 1540067602986201088 1 Twitter 1540067602986201088
Load More

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Home
57

Active Clinical Trials

Home
1300

Participating Institutions

Home
67

International Sites

Home
15000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group